Liver Cirrhosis Research Today is a free monthly online journal that collates and summarizes the latest research about Liver Cirrhosis, including details on alcohol, treatment, drugs, effects, causes.

Response of factor V inhibitor to rituximab in a patient who received liver transplantation for primary biliary cirrhosis.

Lian EC, Tzakis AG, Andrews D

Department of Hematology/Oncology, University of Miami and Veterans Affairs Medical Center, Miami, Florida, USA. elian@med.miami.edu

A 43-year-old patient developed factor V inhibitor 6 months after liver transplantation for primary biliary cirrhosis in association with Sjogren's syndrome/systemic lupus erythematosus. She suffered from ecchymoses in the lower extremities. The factor V inhibitor was eradicated after 10 weekly doses of 375-500 mg/m2 rituximab.

Published 29 November 2004 in Am J Hematol, 77(4): 363-5.
Full-text of this article is available online (may require subscription).

© 2004-2008 Liver Cirrhosis Research Today. All Rights Reserved.